Champlain Investment Partners LLC Sells 106,725 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Champlain Investment Partners LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 53.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 94,221 shares of the company’s stock after selling 106,725 shares during the quarter. Champlain Investment Partners LLC owned approximately 0.11% of IDEXX Laboratories worth $50,873,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Davis R M Inc. raised its stake in shares of IDEXX Laboratories by 2.4% in the first quarter. Davis R M Inc. now owns 98,836 shares of the company’s stock worth $53,365,000 after acquiring an additional 2,321 shares during the last quarter. Cynosure Group LLC bought a new position in IDEXX Laboratories in the 1st quarter worth approximately $355,000. Edgestream Partners L.P. lifted its holdings in IDEXX Laboratories by 124.6% during the 1st quarter. Edgestream Partners L.P. now owns 2,035 shares of the company’s stock worth $1,099,000 after buying an additional 1,129 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in IDEXX Laboratories by 83.0% during the 1st quarter. Acadian Asset Management LLC now owns 4,219 shares of the company’s stock worth $2,276,000 after buying an additional 1,913 shares in the last quarter. Finally, TIAA Trust National Association boosted its position in IDEXX Laboratories by 18.3% in the 1st quarter. TIAA Trust National Association now owns 2,566 shares of the company’s stock valued at $1,385,000 after buying an additional 397 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent research reports. Barclays dropped their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, May 2nd. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a report on Monday, June 24th. Finally, StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $586.63.

IDEXX Laboratories Stock Down 1.0 %

IDXX stock traded down $4.88 during trading hours on Tuesday, reaching $470.41. 397,301 shares of the stock were exchanged, compared to its average volume of 473,066. The firm’s 50-day moving average is $499.04 and its 200-day moving average is $519.06. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The company has a market cap of $38.85 billion, a price-to-earnings ratio of 46.02, a PEG ratio of 3.83 and a beta of 1.32. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, May 1st. The company reported $2.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. IDEXX Laboratories had a return on equity of 63.66% and a net margin of 23.26%. The business had revenue of $964.10 million for the quarter, compared to analyst estimates of $965.43 million. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 11 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In related news, Director Bruce L. Claflin sold 200 shares of the firm’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $540.80, for a total value of $108,160.00. Following the completion of the transaction, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.